Literature DB >> 28007981

Frontline Science: Myeloid-derived suppressor cells (MDSCs) facilitate maternal-fetal tolerance in mice.

Suzanne Ostrand-Rosenberg1, Pratima Sinha2, Chas Figley2, Ramses Long2, DoHwan Park3, Darryl Carter4, Virginia K Clements2.   

Abstract

During successful pregnancy, a woman is immunologically tolerant of her genetically and antigenically disparate fetus, a state known as maternal-fetal tolerance. How this state is maintained has puzzled investigators for more than half a century. Diverse, immune and nonimmune mechanisms have been proposed; however, these mechanisms appear to be unrelated and to act independently. A population of immune suppressive cells called myeloid-derived suppressor cells (MDSCs) accumulates in pregnant mice and women. Given the profound immune suppressive function of MDSCs, it has been suggested that this cell population may facilitate successful pregnancy by contributing to maternal-fetal tolerance. We now report that myeloid cells with the characteristics of MDSCs not only accumulate in the circulation and uterus of female mice following mating but also suppress T cell activation and function in pregnant mice. Depletion of cells with the phenotype and function of MDSCs from gestation d 0.5 through d 7.5 resulted in implantation failure, increased T cell activation, and increased T cell infiltration into the uterus, whereas induction of MDSCs restored successful pregnancy and reduced T cell activation. MDSC-mediated suppression during pregnancy was accompanied by the down-regulation of L-selectin on naïve T cells and a reduced ability of naïve T cells to enter lymph nodes and become activated. Because MDSCs regulate many of the immune and nonimmune mechanisms previously attributed to maternal-fetal tolerance, MDSCs may be a unifying mechanism promoting maternal-fetal tolerance, and their induction may facilitate successful pregnancy in women who spontaneously abort or miscarry because of dysfunctional maternal-fetal tolerance. © Society for Leukocyte Biology.

Entities:  

Keywords:  G-CSF; T cell activation; immune suppression; implantation; myeloid cells; pregnancy

Mesh:

Year:  2016        PMID: 28007981      PMCID: PMC5380379          DOI: 10.1189/jlb.1HI1016-306RR

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   6.011


  58 in total

1.  The terminology issue for myeloid-derived suppressor cells.

Authors:  Dmitry I Gabrilovich; Vincenzo Bronte; Shu-Hsia Chen; Mario P Colombo; Augusto Ochoa; Suzanne Ostrand-Rosenberg; Hans Schreiber
Journal:  Cancer Res       Date:  2007-01-01       Impact factor: 12.701

2.  Endometrial receptivity defects and impaired implantation in diabetic NOD mice.

Authors:  Ahmad J H Albaghdadi; Frederick W K Kan
Journal:  Biol Reprod       Date:  2012-08-02       Impact factor: 4.285

Review 3.  Foxp3+ regulatory T cells: differentiation, specification, subphenotypes.

Authors:  Markus Feuerer; Jonathan A Hill; Diane Mathis; Christophe Benoist
Journal:  Nat Immunol       Date:  2009-07       Impact factor: 25.606

4.  Myeloid-derived suppressor cells are implicated in regulating permissiveness for tumor metastasis during mouse gestation.

Authors:  Laetitia A Mauti; Marie-Aude Le Bitoux; Karine Baumer; Jean-Christophe Stehle; Dela Golshayan; Paolo Provero; Ivan Stamenkovic
Journal:  J Clin Invest       Date:  2011-06-06       Impact factor: 14.808

5.  Primary unexplained infertility is associated with reduced expression of the T-regulatory cell transcription factor Foxp3 in endometrial tissue.

Authors:  Melinda J Jasper; Kelton P Tremellen; Sarah A Robertson
Journal:  Mol Hum Reprod       Date:  2006-03-30       Impact factor: 4.025

6.  Monocytic CCR2(+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment.

Authors:  Alexander M Lesokhin; Tobias M Hohl; Shigehisa Kitano; Czrina Cortez; Daniel Hirschhorn-Cymerman; Francesca Avogadri; Gabrielle A Rizzuto; John J Lazarus; Eric G Pamer; Alan N Houghton; Taha Merghoub; Jedd D Wolchok
Journal:  Cancer Res       Date:  2011-12-15       Impact factor: 12.701

7.  Prevention of allogeneic fetal rejection by tryptophan catabolism.

Authors:  D H Munn; M Zhou; J T Attwood; I Bondarev; S J Conway; B Marshall; C Brown; A L Mellor
Journal:  Science       Date:  1998-08-21       Impact factor: 47.728

8.  Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer.

Authors:  Jinpu Yu; Weijiao Du; Fang Yan; Yue Wang; Hui Li; Shui Cao; Wenwen Yu; Chun Shen; Juntian Liu; Xiubao Ren
Journal:  J Immunol       Date:  2013-02-25       Impact factor: 5.422

9.  Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response.

Authors:  Pratima Sinha; Virginia K Clements; Stephanie K Bunt; Steven M Albelda; Suzanne Ostrand-Rosenberg
Journal:  J Immunol       Date:  2007-07-15       Impact factor: 5.422

Review 10.  Regulatory T cells: new keys for further unlocking the enigma of fetal tolerance and pregnancy complications.

Authors:  Tony T Jiang; Vandana Chaturvedi; James M Ertelt; Jeremy M Kinder; Dayna R Clark; Amy M Valent; Lijun Xin; Sing Sing Way
Journal:  J Immunol       Date:  2014-06-01       Impact factor: 5.422

View more
  31 in total

1.  Antiestrogens in combination with immune checkpoint inhibitors in breast cancer immunotherapy.

Authors:  Diana C Márquez-Garbán; Gang Deng; Begonya Comin-Anduix; Alejandro J Garcia; Yanpeng Xing; Hsiao-Wang Chen; Gardenia Cheung-Lau; Nalo Hamilton; Michael E Jung; Richard J Pietras
Journal:  J Steroid Biochem Mol Biol       Date:  2019-06-19       Impact factor: 4.292

Review 2.  Myeloid-Derived Suppressor Cells and Their Potential Application in Transplantation.

Authors:  Joseph R Scalea; Young Suk Lee; Eduardo Davila; Jonathan S Bromberg
Journal:  Transplantation       Date:  2018-03       Impact factor: 4.939

3.  Toll-like receptor 2 costimulation potentiates the antitumor efficacy of CAR T Cells.

Authors:  Y Lai; J Weng; X Wei; L Qin; P Lai; R Zhao; Z Jiang; B Li; S Lin; S Wang; Q Wu; Z Tang; P Liu; D Pei; Y Yao; X Du; P Li
Journal:  Leukemia       Date:  2017-08-03       Impact factor: 11.528

Review 4.  Recent advances in myeloid-derived suppressor cell biology.

Authors:  Mahmoud Mohammad Yaseen; Nizar Mohammad Abuharfeil; Homa Darmani; Ammar Daoud
Journal:  Front Med       Date:  2020-09-02       Impact factor: 4.592

Review 5.  Myeloid-Derived Suppressor Cells: Immune-Suppressive Cells That Impair Antitumor Immunity and Are Sculpted by Their Environment.

Authors:  Suzanne Ostrand-Rosenberg; Catherine Fenselau
Journal:  J Immunol       Date:  2018-01-15       Impact factor: 5.422

Review 6.  Neutrophil Diversity in Health and Disease.

Authors:  Carlos Silvestre-Roig; Zvi G Fridlender; Michael Glogauer; Patrizia Scapini
Journal:  Trends Immunol       Date:  2019-05-31       Impact factor: 16.687

7.  TAM Family Receptor Kinase Inhibition Reverses MDSC-Mediated Suppression and Augments Anti-PD-1 Therapy in Melanoma.

Authors:  Alisha Holtzhausen; William Harris; Eric Ubil; Debra M Hunter; Jichen Zhao; Yuewei Zhang; Dehui Zhang; Qingyang Liu; Xiaodong Wang; Douglas K Graham; Stephen V Frye; H Shelton Earp
Journal:  Cancer Immunol Res       Date:  2019-08-26       Impact factor: 11.151

Review 8.  Myeloid derived-suppressor cells: their role in cancer and obesity.

Authors:  Suzanne Ostrand-Rosenberg
Journal:  Curr Opin Immunol       Date:  2018-03-13       Impact factor: 7.486

Review 9.  Myeloid-derived suppressor cells coming of age.

Authors:  Filippo Veglia; Michela Perego; Dmitry Gabrilovich
Journal:  Nat Immunol       Date:  2018-01-18       Impact factor: 25.606

10.  Frontline Science: High fat diet and leptin promote tumor progression by inducing myeloid-derived suppressor cells.

Authors:  Virginia K Clements; Tiha Long; Ramses Long; Chas Figley; Daniel M C Smith; Suzanne Ostrand-Rosenberg
Journal:  J Leukoc Biol       Date:  2018-01-03       Impact factor: 4.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.